Additionally, modulation of the angiogenic pathway was observed in prostate cancer cells following treatment with DD1E5: the pro-angiogenic factors VEGF, iNOS, c-Myc, and HIF-1α were all downregulated, indicating that DDAH1 inhibition attenuates the angiogenic potential of DDAH1+ cells (56). Here, NOS2 is linked to prostate carcinoma.